Código QR (código de barras bidimensional)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

BackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of i...

ver descrição completa

Na minha lista:
Principais autores: Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2022-12-01
coleção:Frontiers in Oncology
Assuntos:
neuroblastoma
relapsed
refractory
dinutuximab beta
anti-GD2
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados